Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Mechanisms behind the loss of BCMA in multiple myeloma & options for patients

Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses how the loss of BCMA can occur in patients with multiple myeloma, and further highlights treatment options available when this occurs, including GPRC5D- and FcRH5-targeting agents. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Consulting: Novartis, Roche